Promising mid-stage data in a third indication for efgartigimod have given the Belgian company another boost.
Filgotinib delivers an important win in its first pivotal rheumatoid arthritis study, setting partners Gilead and Galapagos hot on the heels of Abbvie.
Reaction to data from Sangamo's ongoing genome-editing trial shows that small numbers can equal big risks.
Encouraging early data have persuaded the Dutch RNA researcher to push straight into a pivotal trial of its Leber’s congenital amaurosis project, raising hopes for an…
Data from a fixed-dose combination of bempedoic acid and ezetimibe provides some comfort for investors, but the commercial challenge will remain.
Having recently neutralised Erleada, Pfizer moves to challenge earlier use of Zytiga.
Deepmind plans more rigorous trials of its ophthalmology AI after early successes.
Strongbridge will seek accelerated approval for Recorlev after encouraging data, but speed is not the most important factor for success.
Lower factor expression and immune reactions hand big lead to rival Biomarin.